Ernexa Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ERNA Nasdaq 2836 www.ernexatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ernexa Therapeutics Inc.

Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies - Jul 24th, 2026 7:20 am
Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA) - Jul 15th, 2026 7:43 am
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry - Jul 15th, 2026 5:50 am
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026 - Jul 14th, 2026 7:01 am
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients - Jun 25th, 2026 7:15 am
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study - Jun 17th, 2026 6:47 am
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer - Jun 9th, 2026 6:41 am
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development - May 27th, 2026 6:11 am
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - May 20th, 2026 8:45 am
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity - May 20th, 2026 6:31 am
Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners - May 18th, 2026 8:35 am
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 - May 11th, 2026 7:15 am
Ernexa Therapeutics (ERNA) Preclinical Data Shows 100% Survival and Complete Tumor Clearance in Ovarian Cancer Models - May 6th, 2026 8:40 am
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models - May 6th, 2026 6:33 am
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split - Apr 30th, 2026 7:00 am
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026 - Mar 31st, 2026 6:55 am
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series - Feb 20th, 2026 7:05 am
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering - Feb 6th, 2026 7:25 am
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA - Feb 3rd, 2026 6:45 am
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program - Jan 27th, 2026 6:45 am